MedDataX Logo

AutoDx-DR Prospective Clinical Validation Study Protocol

NCT ID: NCT04627272

Last Updated: 2020-11-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

1539 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-12-01

Study Completion Date

2021-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, we will prospectively evaluate the accuracy of a deep-learning based software algorithm in the detection of diabetic retinopathy from 60° wide single-field retinal fundus images.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

We will obtain 60° wide single-field retinal fundus images from subjects who are diabetic patients in primary care environments (i.e. non-eye care settings, such as internal medicine, family medicine, and endocrinology). The fundus images will be uploaded to the RetinaVue Network software using the AutoDx-DR with Over-read modality, where images are transmitted to both AutoDx-DR and a remote ophthalmologist. AutoDx-DR will generate an initial Refer or Not Refer recommendation and the remote ophthalmologist will provide a detailed diagnostic image interpretation which will be used for patient management and referral during the course of the study. AutoDx-DR can also generate a third output which is "Inadequate for Interpretation". In this case, the images will still be sent to the remote ophthalmologist for interpretation. If the ophthalmologist also cannot interpret the images, the patient will be recommended to have an in-person comprehensive ophthalmologic exam.

Subjects participating in this study will undergo further retinal fundus imaging: four mydriatic, stereoscopic 45° field of view (4W) retinal images and spectral domain optical coherence tomography (SD-OCT) captured with the Reference Standard Camera (i.e. Zeiss Cirrus 600 photo, or other appropriate FDA-cleared imaging device with stereo fundus photography and SD-OCT capability that meets the requirements of the certified fundus photography reading center such as Topcon, Optovue, and Heidelberg). The 4W and SD-OCT imaging will be performed by a certified technician located at or near the enrolling study site. The 4W and SD-OCT images will be interpreted by a certified fundus photography reading center (FPRC) for more than mild DR or any diabetic macular edema. The FPRC's Not Refer/Refer determination will be used as the "gold standard" interpretation in this study.

The AutoDx-DR interpretation of the 60° wide single-field images will be compared to the FPRC "gold standard" interpretation for the Not Refer/Refer recommendation. Accuracy metrics of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (PLR), and negative likelihood ratio (NLR), with 95% confidence intervals will be calculated. All diabetic patients who are attending routine primary care or endocrinology appointments and meet the enrollment criteria will be invited to participate in the study. All study procedures will be performed during a single study visit.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Retinopathy

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Diabetic Retinopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

This is a study to determine the accuracy of AutoDX. All eligible study participants will have a retinal fundus image taken which is then uploaded to the RetinaVue Network. Subjects will also undergo further retinal fundus imaging: four mydriatic, stereoscopic 45° field of view (4W) retinal images and spectral domain optical coherence tomography (SD-OCT) captured with the Reference Standard Camera.
Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AutoDX and Gold Standard

A licensed clinician will obtain 60° wide single-field retinal fundus images from subjects who are diabetic patients in primary care environments (i.e. non-eye care settings, such as internal medicine, family medicine, and endocrinology). The fundus images will be uploaded to the RetinaVue Network software using the AutoDx-DR with Over-read modality, where images are transmitted to both AutoDx-DR and a remote ophthalmologist. Subjects participating in this study will undergo further retinal fundus imaging: four mydriatic, stereoscopic 45° field of view (4W) retinal images and spectral domain optical coherence tomography (SD-OCT) captured with the Reference Standard Camera

Group Type EXPERIMENTAL

AutoDX-DR

Intervention Type DEVICE

AutoDx-DR provides basic image interpretation for the detection of DR and diabetic macular edema (DME) and a Refer or Not Refer recommendation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AutoDX-DR

AutoDx-DR provides basic image interpretation for the detection of DR and diabetic macular edema (DME) and a Refer or Not Refer recommendation.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

A documented diagnosis of diabetes mellitus in accordance with the criteria established by the American Diabetes Association (ADA)7 as indicated by at least one of the following:

* Hemoglobin A1c (HbA1c) \> 6.5%
* Fasting Plasma Glucose (FPG; period of fasting must be at least 8 hours) \> 126 mg/dL (7.0 mmol/L)
* Oral Glucose Tolerance Test (OGTT) with 2-hour plasma glucose \>200 mg/dL (11.1 mmol/L), using the equivalent of an oral 75 g anhydrous glucose dose dissolved in water o Symptoms of hyperglycemia or hyperglycemic crisis with a random plasma glucose (RPG) ≥ 200 mg/dL (11.1 mmol/L)

* 22 years of age or older
* Ability to understand the study and sign the informed consent

Exclusion Criteria

* A documented diagnosis of more than mild diabetic retinopathy in the patient record.

o More than mild diabetic retinopathy shall be defined as moderate NPDR, severe NPDR, proliferative diabetic retinopathy (PDR) or any level of DME; or a documented diabetic eye exam report indicating more than microaneurysms \[i.e. presence of intraretinal hemorrhages, venous beading, intraretinal microvascular abnormalities (IRMA,) neovascularization or DME.\]
* They report having severe vision loss in both eyes.
* They report a history of laser treatment or surgery of the retina.
* They report that they are currently receiving treatment for DR or DME.
* They report a diagnosis of angle closure glaucoma.
* They report hypersensitivity to light which makes retinal imaging uncomfortable.
* They are currently pregnant or breastfeeding.
* They report that they have an iris supported intraocular lens or anterior chamber intraocular lens associated with a previous cataract surgery.
* They had a previous pupilloplasty surgery.
Minimum Eligible Age

22 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Rho, Inc.

INDUSTRY

Sponsor Role collaborator

ClinEdge

INDUSTRY

Sponsor Role collaborator

Hill-Rom

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Antonio Piñero-Piloña, MD

Role: PRINCIPAL_INVESTIGATOR

Diabetes Care Center

Joseph Woolley, MD

Role: PRINCIPAL_INVESTIGATOR

Southwest Internal Medicine

Keila Hoover, MD

Role: PRINCIPAL_INVESTIGATOR

Hoover Family Medicine

Quang Vo, MD

Role: PRINCIPAL_INVESTIGATOR

Dr. Steven Barag, DO

Peter Mattar, MD

Role: PRINCIPAL_INVESTIGATOR

Dr. Peter N. Mattar, MD

Efrain Soto, MD

Role: PRINCIPAL_INVESTIGATOR

Park Lakes Family Medicine

Harish Thakkar, MD

Role: PRINCIPAL_INVESTIGATOR

Southwest Medical Clinic

Luis Gonzalez-Orozco, MD

Role: PRINCIPAL_INVESTIGATOR

Clinic of Luis Gonzalez

Jennifer Bellucci-Jackson, MD

Role: PRINCIPAL_INVESTIGATOR

Family Medicine Specialists

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Elizabeth Downs

Role: CONTACT

Phone: 9893394131

Email: [email protected]

Lindsay E Downing

Role: CONTACT

Phone: 8043070924

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

60095127

Identifier Type: -

Identifier Source: org_study_id